Feasibility & Efficacy of Durvalumab+Tremelimumab+RT and Durvalumab+RT in Non-resect. Locally Advanced HPVnegativ HNSCC

Condition:   Squamous Cell Carcinoma of the Head and Neck
Interventions:   Drug: Durvalumab;   Drug: Tremelimumab;   Radiation: Radiotherapy
Sponsors:   Ulrich Keilholz;   Charite University, Berlin, Germany;   AstraZeneca
Not yet recruiting

https://ift.tt/2MAxHoV